Immune thrombocytopenia (ITP) trials in Japan
5 of 6 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Bunkyō-Ku, Chuo-ku, Hirakata-shi, Ibaraki, Iruma-gun, Kofu, Narashino-shi, Osaka, Sendai, Suita-shi, Sumida-ku, tabashi City, Yokohama
- Age
- 18 years and over
- People
- 171 worldwide
- Run by
- Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00 - Phase 3Taking peopleA Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Bunkyō-Ku, Chuo-ku, Hirakata-shi, Ibaraki, Iruma-gun, Kofu, Narashino-shi, Osaka, Sendai, Suita-shi, Sumida-ku, tabashi City, Yokohama
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00 - Phase 2/3Taking peopleA Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
- Where
- Kobe, Osaka, Sapporo
- Age
- 12 years to 17 years
- People
- 24 worldwide
- Run by
- argenx
See details and how to joinNCT07194850 · EU 2025-521055-23-00 - Phase 1Taking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Bunkyo-ku, Hamamatsu, Himeji, Isehara, Kodaira, Okayama, Ōta-ku, Sakai, Sapporo, Sendai, Suita, Toyama
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - Phase 1Enrolling by invitationPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Bunkyo-ku, Fukuoka, Hamamatsu, Himeji, Isehara, Kawachi-Nagano, Kodaira, Meguro-Ku, Okayama, Ōta-ku, Sakai, Sapporo, Sendai, Suita, Toyama
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106